Get the Stockscreener App
3.26
1.21%
-0.04
After Hours:
3.26
X 4 Pharmaceuticals Inc stock is traded at $3.26, with a volume of 267.76K.
It is down -1.21% in the last 24 hours and up +26.36% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.30
Open:
$3.31
24h Volume:
267.76K
Relative Volume:
0.07
Market Cap:
$37.19M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.3392
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
-6.86%
1M Performance:
+26.36%
6M Performance:
-68.25%
1Y Performance:
-83.97%
1-Day Range:
$3.20
$3.40
1-Week Range:
$3.05
$3.60
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.26 | 76.10M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
X4 Pharmaceuticals Inc. stock prediction for this weekWeekly Trade Report & Free High Accuracy Swing Entry Alerts - Newser
Is X4 Pharmaceuticals Inc. trending in predictive chart modelsWeekly Stock Report & Technical Analysis for Trade Confirmation - Newser
X4 Pharmaceuticals Inc. stock trend forecastQuarterly Market Review & Accurate Buy Signal Notifications - Newser
analyzing x4 pharmaceuticals inc. with risk reward ratio chartsJuly 2025 Fed Impact & Weekly Setup with ROI Potential - Newser
Using R and stats models for X4 Pharmaceuticals Inc. forecastingJuly 2025 Technicals & AI Driven Price Forecasts - Newser
Price momentum metrics for X4 Pharmaceuticals Inc. explainedWeekly Trade Recap & Risk Controlled Swing Trade Alerts - Newser
What technical models suggest about X4 Pharmaceuticals Inc.’s comeback - Newser
Relative strength of X4 Pharmaceuticals Inc. in sector analysis2025 Sector Review & Accurate Entry/Exit Alerts - Newser
Long term hold vs stop loss in X4 Pharmaceuticals Inc.Trade Entry Summary & Low Volatility Stock Suggestions - Newser
Analyzing drawdowns of X4 Pharmaceuticals Inc. with statistical toolsJuly 2025 Earnings & Real-Time Sentiment Analysis - Newser
X4 Pharmaceuticals Inc. stock trendline breakdownTrade Analysis Summary & Free High Return Stock Watch Alerts - Newser
How to use a screener to detect X4 Pharmaceuticals Inc. breakouts2025 Winners & Losers & Weekly Return Optimization Alerts - Newser
What the charts say about X4 Pharmaceuticals Inc. todayWeekly Market Outlook & Precise Buy Zone Tips - Newser
Using RSI to spot recovery in X4 Pharmaceuticals Inc.Portfolio Update Summary & Stepwise Entry and Exit Trade Signals - Newser
Is X4 Pharmaceuticals Inc. forming a reversal patternRecession Risk & AI Forecast Swing Trade Picks - Newser
Real time scanner hits for X4 Pharmaceuticals Inc. explainedQuarterly Trade Review & Daily Risk Controlled Trade Plans - Newser
Is X4 Pharmaceuticals Inc. showing signs of accumulationMarket Movers & Long-Term Growth Plans - Newser
Real time breakdown of X4 Pharmaceuticals Inc. stock performanceWeekly Trade Summary & Low Drawdown Investment Strategies - Newser
Trend analysis for X4 Pharmaceuticals Inc. this weekJuly 2025 Selloffs & Intraday High Probability Setup Alerts - Newser
X4 pharmaceuticals files for offering of up to 59.9 million shares of common stock by the selling stockholdersSEC filing - MarketScreener
Detecting price anomalies in X4 Pharmaceuticals Inc. with AIWeekly Risk Report & Target Return Focused Picks - Newser
Using data tools to time your X4 Pharmaceuticals Inc. exitPortfolio Return Summary & Low Risk Investment Opportunities - Newser
Analyzing X4 Pharmaceuticals Inc. with risk reward ratio chartsPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
What to expect from X4 Pharmaceuticals Inc. in the next 30 daysPortfolio Risk Report & Free Technical Pattern Based Buy Signals - Newser
X4 Pharmaceuticals Inc. stock daily chart insights2025 Geopolitical Influence & Capital Protection Trading Alerts - Newser
Risk vs reward if holding onto X4 Pharmaceuticals Inc.Quarterly Portfolio Review & Daily Momentum Trading Reports - Newser
Will X4 Pharmaceuticals Inc. outperform the marketLong Setup & Advanced Technical Analysis Signals - Newser
Will X4 Pharmaceuticals Inc. continue its uptrendJuly 2025 Patterns & Community Consensus Trade Alerts - Newser
Will X4 Pharmaceuticals Inc. price bounce be sustainableQuarterly Market Summary & Stepwise Entry and Exit Trade Signals - Newser
Is X4 Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Fed Impact & Community Shared Stock Ideas - Newser
analyzing drawdowns of x4 pharmaceuticals inc. with statistical tools2025 Support & Resistance & Long-Term Growth Stock Strategies - Newser
Forecasting X4 Pharmaceuticals Inc. price range with options dataRate Hike & Weekly Watchlist of Top Performers - Newser
Sitryx appoints Adam Mostafa as Chief Financial Officer - GlobeNewswire Inc.
X4 Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Risk Summary & Long-Term Safe Investment Plans - Newser
Has X4 Pharmaceuticals Inc. formed a bullish divergenceWeekly Trade Recap & Free Low Drawdown Momentum Trade Ideas - Newser
What are analysts’ price targets for X4 Pharmaceuticals Inc.Quarterly Profit Summary & AI Enhanced Trading Alerts - beatles.ru
Intraday pattern recognizer results for X4 Pharmaceuticals Inc.New Guidance & Free Technical Pattern Based Buy Signals - Newser
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):